You are here: Industry Insights > cancer

News List

NICE no for BMS’ Opdivo for head and neck cancer pharmatimes
January 11, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has turned down Bristol Myers Squibb’s (BMS) immunotherapy Opdivo (nivolumab) for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) after platinum-based ...
First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom prnasia
January 08, 2021
RhoVac AB announces, on January 7th, 2021, that the first patient in United Kingdom is enrolled in the company's clinical phase IIb study in prostate cancer, a study named RhoVac-002 ("BRaVac").
Gracell Biotechnologies Announces Pricing of Initial Public Offering prnasia
January 08, 2021
Gracell Biotechnologies Inc. announced the pricing of its initial public offering of 11,000,000 American Depositary Shares ("ADSs"), each representing five ordinary shares, at a public offering price of US$19.00 per ADS.
New Resource for Survivors from NCCN Helps Guide Life After Cancer Diagnosis and Treatment prnasia
January 06, 2021
The National Comprehensive Cancer Network® (NCCN®) announced the publication of new, free informational resources on health and wellness for cancer survivors.
CRUK scientists develop drug that targets KRAS pathways pharmatimes
January 05, 2021
A new study, funded by Cancer Research UK (CRUK) and Wellcome, has discovered a new way to target the KRAS mutation, which is found in a number of hard-to-treat cancer types.
Oncorus to Build GMP Viral Immunotherapy Mfg. Facility contractpharma
January 05, 2021
Oncorus, Inc., a clinical stage biopharmaceutical company developing next-gen viral immunotherapies for cancer, has signed a 15-year lease to build a state-of-the-art, 88,000 sq.-ft. GMP viral immunotherapy clinical manufacturing facility in Andover ...
Lantern Pharma Launches ADC Program contractpharma
January 05, 2021
Lantern Pharma, a clinical-stage biopharma company using its RADR artificial intelligence platform to advance cancer drug development, is launching the development of its ADC (Antibody Drug Conjugate) program through an evaluation and potential ...
Tel Aviv University develops novel lipid nanoparticle-based delivery system to destroy cancer cells expresspharma
January 05, 2021
The system, called CRISPR-LNPs, carries a genetic messenger (messenger RNA), which encodes for the CRISPR enzyme Cas9 that acts as molecular scissors that cut the cells’ DNA.
Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment prnewswire
January 04, 2021
Hoth Therapeutics, Inc., a biopharmaceutical company, announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001 with Tergus Pharma for its novel cancer treatment drug, HT-001.
Concord Medical Announces Divestment of Singapore Concord International Hospital prnasia
December 29, 2020
Concord Medical Services Holdings Limited, a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 87 88 Next page